Amarna opts for former Novartis exec Aurelia Caparrós as CBO

19 April 2024
aurelia-caparros-large

Former Novartis (NOVN: VX) executive Aurelia Caparrós (pictured above) has joined Amarna Therapeutics, a privately-held Dutch biotech developing gene therapies in a range of rare and prevalent diseases, including type 1 diabetes.

Ms Caparrós, who has been working as an executive coach since leaving her role as oncology commercial head for the Swiss pharma giant in February last year, becomes Amarna’s chief business officer (CBO).

She brings more than 25 years of healthcare industry experience with expertise in business development, strategy and global marketing including P&L responsibilities spanning diverse geographies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology